A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer

This study is testing a new type of treatment for unresectable pancreatic cancer using the patient's own white blood cells (neutrophils) that have been loaded with anti-cancer drugs. These cells are then reinfused into the patient, where they may deliver the drug directly to the tumor. **You may be eligible if...** - You are 18–70 years old - You have been confirmed to have pancreatic cancer that cannot be removed with surgery - You have either already tried standard treatments that haven't worked, or you are choosing this new therapy voluntarily - You are in reasonable health (ECOG ≤ 2) with an expected survival of at least 3 months - Your liver, kidney, and blood counts are adequate **You may NOT be eligible if...** - You require blood-thinning (anticoagulant) therapy - You have an active infection, or a history of bone marrow or organ transplantation - You have an autoimmune or auto-inflammatory disease Talk to your doctor to see if this trial is right for you.